WuXi Biologics breaks ground on CRDMO center in Singapore

“WuXi Biologics Singapore CRDMO center will strengthen Singapore’s biopharmaceutical sector, which comprises global healthcare companies operating industry leading manufacturing and R&D facilities, complemented by a strong local R&D and start-up ecosystem. This investment will create significant employment opportunities for Singaporeans, and spur collaborations between WuXi Biologics, our R&D institutions and startups to develop innovative therapeutics and novel modalities. Singapore continues to welcome global healthcare players seeking to innovate, manufacture and commercialize end-to-end solutions for clients worldwide.”

“As the master planner and developer for Singapore's industrial estates, JTC is committed to cultivating a collaborative ecosystem of like-minded partners within our estates to strengthen Singapore's position as a biomedical sciences hub. We are delighted that WuXi Biologics will be establishing its CRDMO center in Tuas Biomedical Park to be part of our ecosystem.”

"We are excited to enhance our capacity and geographic footprint by building a new CRDMO center in Singapore to serve the growing demands from the global and emerging Asia-Pacific markets. Our Singapore CRDMO center will provide high-quality and more cost-efficient end-to-end CRDMO services near where our clients operate through our Global Dual Sourcing strategy. As we continue to strengthen our global network, elevate our capacity and capabilities, and advance our technology platforms, we are better positioned to accelerate and transform the discovery, development and manufacturing of innovative biologics to enable global clients to bring their breakthrough therapeutics to patients worldwide.”